About us
 |
C.E.L.forpharma stands for “Centre for Executive Leadership for the pharmaceutical industry” and has been created in January 2005 to offer a range of international special-topics training services with the support of reputable pharma industry expert-consultants and organizations. |
History |
||
2005 |
|
|
2006 |
|
|
2007 |
|
|
2008 |
|
|
2009 |
|
Founders |
||
|
Edouard Demeire, Managing Partner
|
|
|
Luc De Langhe, Managing Director
|
Staff |
||
|
Marie Stricklesse Programme Coordinator Marie is responsible for the flawless organization of all our courses and seminars. She coordinates all activities that result in a well-organized training experience for the participants. She is the point of contact for our participants as well as for the expert faculty, hotels and other suppliers we work with. |
|
|
Annelies Swaan Marketing Associate Annelies is responsible for establishing and building strong and lasting relationships with our client companies. She is involved in communication and account management projects that must ensure we develop mutually beneficial relationships with our clients. |
Experts
|
||
|
Edouard Demeire Managing Director, Prism Edouard Demeire uniquely combines in-depth pharma marketing expertise with academic rigour and a wealth of training experience all over the globe. His teaching, consulting and research focus is on systematic decision support tools and models for pharma marketing strategy. He developed the very successful STRATPHARM business simulation game in collaboration with Prof. Marcel Corstjens of INSEAD. |
|
|
Martin Austin Managing Director, TransformRX Martin Austin has a strong reputation in Europe’s senior (bio)pharma business development community. His profile uniquely combines the expertise and experience of a high-profile pharma business development executive with that of a senior life science capital investment officer. Between 1996 and 2000, Martin was Roche’s global Head of Business Development for Pharmaceuticals. During that period he had a leading role in the establishment of Roche Genetics, the rationalisation of the R&D portfolio, which led to the establishment of Actelion, Basilea and BioXell, as well as in the acquisition and integration of Boehringer Mannheim. After that, until January 2005, he was a Principal with Paul Capital Partners, a global private equity firm, leading their European Royalty healthcare activities. In 2005, Martin founded TransformRx to provide business advice to clients regarding investment and business development opportunities. Martin is also a faculty member of the “European Course for BioBusiness Development” at the University of Basel. |
|
|
Fonny Schenck European thought leader on digital and customer-centric innovation in the new go-to-market model of life sciences. Since mid 2007, Fonny Schenck has been CEO of Across Health, a fast-growing international consultancy on customer-centric innovation in life sciences. He joined from Johnson & Johnson, where he held regional and global roles in the e-business and CRM space between 2000 and 2007. In addition, he managed the EMEA-wide Salesforce Effectiveness programme as well as the launch of the Marketing Excellence programme. Leveraging his extensive hands-on experience, Fonny is focused on helping international clients to navigate towards a new commercial model, through the selective adoption of impactful innovative customer approaches. Fonny likes to work at the exciting intersection of technology, commercial effectiveness, business strategy and innovation. One of his more recent strategic focus areas is the impact of connected healthcare on the business model for pharma. Fonny has received many awards at J&J for his achievements in the CRM and e-business space, both at the European and global level. In addition, he is a well-known speaker at international CRM and e-marketing events and has authored several strategic eCRM articles. |
|
|
Gary Johnson Founder and CEO of Inpharmation As the founder and Managing Director of Inpharmation, a consultancy specializing in pharma forecasting and modelling, Gary Johnson works with the world's top 10 pharma companies and many more. |
|
|
Prof. Dr. Lieven Annemans Full Professor of Health Economics at Ghent University and Brussels University Lieven Annemans is a Full Professor of Health Economics at Ghent University and Brussels University. He is Past-President of ISPOR, the International Society for PharmacoEconomics and Outcomes Research, chairman of the Flemish Health Council (advising the Minister of Health), and external expert to the Belgian HTA body “KCE”. He has experience in health- economic evaluations of pharmaceutical drugs, medical devices and preventive health actions in various medical areas, and conducted studies in over 20 countries. He is currently also active as an independent consultant in health economics and prior to his professorship he has also worked in the pharma industry. |
|
|
Dr. Neal Hansen Global Director of Consulting, Datamonitor Healthcare Neal is the Global Director of Datamonitor’s Healthcare Consulting Practice. In this role, he leads a multi-disciplinary team focusing on the provision of customized solutions to leading players in the pharmaceutical and biotechnology industries in key areas such as portfolio and brand management, in- and out-licensing and forecasting. |
|
|
Lloyd Morgan General Manager, Adelphi Group Ltd Lloyd Morgan is the General Manager of Adelphi Group. Lloyd has worked with Adelphi for over 19 years and has experience in communications, outcomes and marketing research. He is a member of Adelphi’s pricing consultancy team. Lloyd originally trained as an accountant and his previous experience included involvement in the European launch of Tenormin when working with AstraZeneca. Lloyd is a member of the Market Research Society. |
|
|
Konrad Wallerstein Director, Adelphi Focus Konrad Wallerstein is based in Adelphi’s Philadelphia office. Konrad has 20 years of experience in working on pricing, reimbursement and market access issues within the industry and as a consultant. Prior to starting Adelphi Focus, Konrad was Executive Director, Pricing at J&J PGSM HE&P, leader of the Public Policy practice at Cambridge Pharma Consultants, where he also devised and implemented PharmaQuery (an international on-line information resource, newsletter and consultative service dedicated to market access systems and issues), and a founding director of REMIT (one of the first consultancies to focus on the economic and commercial aspects of pharmaceuticals, for the industry, trade associations, governments and the European Commission). |
|
|
David Scott Freelance licensing and business development consultant with over 24 years of licensing experience in the healthcare sector - the first ten years within the pharma industry. David Scott is a freelance healthcare consultant and a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products, delivery systems and technologies. He has also provided licensing training for a number of multinational pharma companies and training organisations and has published widely. David has a BSc in Chemistry from Nottingham and post-graduate qualifications in marketing and market research from Kingston Business School. He is also an accredited Certified Licensing Professional and a member of the Licensing Executives Society and the Pharmaceutical Licensing Group. He joined Fisons plc (acquired by RPR in 1995, which itself has been acquired by Sanofi-aventis) in 1973 where he held a number of roles including marketing, corporate development, finance director of their Spanish subsidiary, business development manager and licensing. As Fisons Licensing Manager, he closed a number of major deals and collaborative ventures involving both drugs and delivery systems. David has been spending the past 13 years as a consultant and has provided strategic advice. He has successfully concluded both inward and outward licensing agreements on behalf of a range of worldwide clients. His client base includes top ranking global companies, European regional companies, biotech companies, technology start-ups and universities. He currently sits on the board of three UK-based pharmaceutical businesses. |
|
|
Dr. Patrik Frei Founder and CEO of Venture Valuation AG Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland. Venture Valuation specializes in independent, third party assessment and valuation of emerging high growth companies in biotechnology and life sciences. Services are provided in the form of proprietary Valuation Reports(TM) to companies and investors. Furthermore, Venture Valuation runs the Biotech and Life Sciences Databases Biotechgate and other country databases in Austria, Canada, France, Germany, India, Italy and Switzerland. |
|
|
Johan Ohlsson Sr Consultant with a background in research (Karolinska Institute) and strategic analysis. Johan Ohlsson is currently employed as a Business Analyst at Venture Valuation AG, Switzerland, performing independent third-party financial and strategy evaluations of emerging high-growth companies in the area of life sciences. Johan holds a MSc. in Molecular Biology and a BSc. in Finance from the Södertörn University. He also held various positions within Pharmalicensing as a business development executive and strategic analyst focused on business development where he played an active role in product development and started a consulting division focused on business development activities. Prior to that, he worked as an oncology researcher at the Microbiology and Tumor Biology Centre (MTC), Karolinska Institutet, and later as an Analyst at the Bioseeker Group. |
